Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 299

1.

Immune Correlates of Disease Progression in Linked HIV-1 Infection.

Tuen M, Bimela JS, Banin AN, Ding S, Harkins GW, Weiss S, Itri V, Durham AR, Porcella SF, Soni S, Mayr L, Meli J, Torimiro JN, Tongo M, Wang X, Kong XP, Nádas A, Kaufmann DE, Brumme ZL, Nanfack AJ, Quinn TC, Zolla-Pazner S, Redd AD, Finzi A, Gorny MK, Nyambi PN, Duerr R.

Front Immunol. 2019 May 14;10:1062. doi: 10.3389/fimmu.2019.01062. eCollection 2019.

2.

Leveraging Knowledge Representation to Maintain Immunization Clinical Decision Support.

Mathe JL, Nelson SD, Weinberg ST, Lehmann CU, Nadas A, Weitkamp AO.

AMIA Annu Symp Proc. 2018 Dec 5;2018:789-798. eCollection 2018.

3.

Characterization of AHR2 and CYP1A expression in Atlantic sturgeon and shortnose sturgeon treated with coplanar PCBs and TCDD.

Roy NK, Candelmo A, DellaTorre M, Chambers RC, Nádas A, Wirgin I.

Aquat Toxicol. 2018 Apr;197:19-31. doi: 10.1016/j.aquatox.2018.01.017. Epub 2018 Feb 2.

4.

Functional Antibody Response Against V1V2 and V3 of HIV gp120 in the VAX003 and VAX004 Vaccine Trials.

Balasubramanian P, Williams C, Shapiro MB, Sinangil F, Higgins K, Nádas A, Totrov M, Kong XP, Fiore-Gartland AJ, Haigwood NL, Zolla-Pazner S, Hioe CE.

Sci Rep. 2018 Jan 11;8(1):542. doi: 10.1038/s41598-017-18863-0.

5.

Multimethod Longitudinal HIV Drug Resistance Analysis in Antiretroviral-Therapy-Naive Patients.

Nanfack AJ, Redd AD, Bimela JS, Ncham G, Achem E, Banin AN, Kirkpatrick AR, Porcella SF, Agyingi LA, Meli J, Colizzi V, Nádas A, Gorny MK, Nyambi PN, Quinn TC, Duerr R.

J Clin Microbiol. 2017 Sep;55(9):2785-2800. doi: 10.1128/JCM.00634-17. Epub 2017 Jun 28.

6.

Differential induction of anti-V3 crown antibodies with cradle- and ladle-binding modes in response to HIV-1 envelope vaccination.

Balasubramanian P, Kumar R, Williams C, Itri V, Wang S, Lu S, Hessell AJ, Haigwood NL, Sinangil F, Higgins KW, Liu L, Li L, Nyambi P, Gorny MK, Totrov M, Nadas A, Kong XP, Zolla-Pazner S, Hioe CE.

Vaccine. 2017 Mar 7;35(10):1464-1473. doi: 10.1016/j.vaccine.2016.11.107. Epub 2017 Feb 6.

7.

Effects of hookah smoking on indoor air quality in homes.

Weitzman M, Yusufali AH, Bali F, Vilcassim MJR, Gandhi S, Peltier R, Nadas A, Sherman S, Lee L, Hong Z, Shearston J, Park SH, Gordon T.

Tob Control. 2016 Sep;26(5):586-591. doi: 10.1136/tobaccocontrol-2016-053165. Epub 2016 Oct 26.

8.

Functional and Structural Characterization of Human V3-Specific Monoclonal Antibody 2424 with Neutralizing Activity against HIV-1 JRFL.

Kumar R, Pan R, Upadhyay C, Mayr L, Cohen S, Wang XH, Balasubramanian P, Nádas A, Seaman MS, Zolla-Pazner S, Gorny MK, Kong XP, Hioe CE.

J Virol. 2015 Sep;89(17):9090-102. doi: 10.1128/JVI.01280-15. Epub 2015 Jun 24.

9.

A broad range of mutations in HIV-1 neutralizing human monoclonal antibodies specific for V2, V3, and the CD4 binding site.

Li L, Wang XH, Williams C, Volsky B, Steczko O, Seaman MS, Luthra K, Nyambi P, Nadas A, Giudicelli V, Lefranc MP, Zolla-Pazner S, Gorny MK.

Mol Immunol. 2015 Aug;66(2):364-74. doi: 10.1016/j.molimm.2015.04.011. Epub 2015 May 18.

10.

An Electronic Tool for the Evaluation and Treatment of Sepsis in the ICU: A Randomized Controlled Trial.

Semler MW, Weavind L, Hooper MH, Rice TW, Gowda SS, Nadas A, Song Y, Martin JB, Bernard GR, Wheeler AP.

Crit Care Med. 2015 Aug;43(8):1595-602. doi: 10.1097/CCM.0000000000001020.

11.

Could vaccination with AIDSVAX immunogens have resulted in antibody-dependent enhancement of HIV infection in human subjects?

Shmelkov E, Nadas A, Cardozo T.

Hum Vaccin Immunother. 2014;10(10):3013-6. doi: 10.4161/21645515.2014.972148. Epub 2014 Nov 21.

12.

Distinct mechanisms regulate exposure of neutralizing epitopes in the V2 and V3 loops of HIV-1 envelope.

Upadhyay C, Mayr LM, Zhang J, Kumar R, Gorny MK, Nádas A, Zolla-Pazner S, Hioe CE.

J Virol. 2014 Nov;88(21):12853-65. doi: 10.1128/JVI.02125-14. Epub 2014 Aug 27.

13.

The effect of particle size, location and season on the toxicity of urban and rural particulate matter.

Mirowsky J, Hickey C, Horton L, Blaustein M, Galdanes K, Peltier RE, Chillrud S, Chen LC, Ross J, Nadas A, Lippmann M, Gordon T.

Inhal Toxicol. 2013 Nov;25(13):747-57. doi: 10.3109/08958378.2013.846443.

14.

Elicitation of broadly reactive antibodies against glycan-modulated neutralizing V3 epitopes of HIV-1 by immune complex vaccines.

Kumar R, Tuen M, Liu J, Nàdas A, Pan R, Kong X, Hioe CE.

Vaccine. 2013 Nov 4;31(46):5413-21. doi: 10.1016/j.vaccine.2013.09.010. Epub 2013 Sep 16.

15.

Endogenous osteopontin promotes ozone-induced neutrophil recruitment to the lungs and airway hyperresponsiveness to methacholine.

Barreno RX, Richards JB, Schneider DJ, Cromar KR, Nadas AJ, Hernandez CB, Hallberg LM, Price RE, Hashmi SS, Blackburn MR, Haque IU, Johnston RA.

Am J Physiol Lung Cell Mol Physiol. 2013 Jul 15;305(2):L118-29. doi: 10.1152/ajplung.00080.2013. Epub 2013 May 10.

16.

Cross-neutralizing activity of human anti-V3 monoclonal antibodies derived from non-B clade HIV-1 infected individuals.

Andrabi R, Williams C, Wang XH, Li L, Choudhary AK, Wig N, Biswas A, Luthra K, Nadas A, Seaman MS, Nyambi P, Zolla-Pazner S, Gorny MK.

Virology. 2013 May 10;439(2):81-8. doi: 10.1016/j.virol.2012.12.010. Epub 2013 Mar 5.

17.

Different pattern of immunoglobulin gene usage by HIV-1 compared to non-HIV-1 antibodies derived from the same infected subject.

Li L, Wang XH, Banerjee S, Volsky B, Williams C, Virland D, Nadas A, Seaman MS, Chen X, Spearman P, Zolla-Pazner S, Gorny MK.

PLoS One. 2012;7(6):e39534. doi: 10.1371/journal.pone.0039534. Epub 2012 Jun 25.

18.

Aromatase inhibitors--a viable option for recurrent granulosa cell tumour of ovary: overview and case report.

Abdul Munem A, Al-Bahrani B, Mehdi I, Kamona A, Nadas AM.

J Pak Med Assoc. 2012 May;62(5):505-7. Review.

19.

Superinfection by discordant subtypes of HIV-1 does not enhance the neutralizing antibody response against autologous virus.

Mayr LM, Powell RL, Ngai JN, Takang WA, Nádas A, Nyambi PN.

PLoS One. 2012;7(6):e38989. doi: 10.1371/journal.pone.0038989. Epub 2012 Jun 14.

20.

Randomized trial of automated, electronic monitoring to facilitate early detection of sepsis in the intensive care unit*.

Hooper MH, Weavind L, Wheeler AP, Martin JB, Gowda SS, Semler MW, Hayes RM, Albert DW, Deane NB, Nian H, Mathe JL, Nadas A, Sztipanovits J, Miller A, Bernard GR, Rice TW.

Crit Care Med. 2012 Jul;40(7):2096-101. doi: 10.1097/CCM.0b013e318250a887.

21.

Indirect detection of an epitope-specific response to HIV-1 gp120 immunization in human subjects.

Shmelkov E, Nadas A, Swetnam J, Zolla-Pazner S, Cardozo T.

PLoS One. 2011;6(11):e27279. doi: 10.1371/journal.pone.0027279. Epub 2011 Nov 4.

22.

Global levels of histone modifications in peripheral blood mononuclear cells of subjects with exposure to nickel.

Arita A, Niu J, Qu Q, Zhao N, Ruan Y, Nadas A, Chervona Y, Wu F, Sun H, Hayes RB, Costa M.

Environ Health Perspect. 2012 Feb;120(2):198-203. doi: 10.1289/ehp.1104140. Epub 2011 Oct 24.

23.

In vitro restoration of Th17 response during HIV infection with an antiretroviral drug and Th17 differentiation cytokines.

Alvarez Y, Tuen M, Nàdas A, Hioe CE.

AIDS Res Hum Retroviruses. 2012 Aug;28(8):823-34. doi: 10.1089/AID.2011.0184. Epub 2011 Dec 1.

24.

HIV envelope gp120 activates LFA-1 on CD4 T-lymphocytes and increases cell susceptibility to LFA-1-targeting leukotoxin (LtxA).

Hioe CE, Tuen M, Vasiliver-Shamis G, Alvarez Y, Prins KC, Banerjee S, Nádas A, Cho MW, Dustin ML, Kachlany SC.

PLoS One. 2011;6(8):e23202. doi: 10.1371/journal.pone.0023202. Epub 2011 Aug 5.

25.

Cross-clade HIV-1 neutralizing antibodies induced with V3-scaffold protein immunogens following priming with gp120 DNA.

Zolla-Pazner S, Kong XP, Jiang X, Cardozo T, Nádas A, Cohen S, Totrov M, Seaman MS, Wang S, Lu S.

J Virol. 2011 Oct;85(19):9887-98. doi: 10.1128/JVI.05086-11. Epub 2011 Jul 27.

26.

Fine particulate matter constituents associated with cardiovascular hospitalizations and mortality in New York City.

Ito K, Mathes R, Ross Z, Nádas A, Thurston G, Matte T.

Environ Health Perspect. 2011 Apr;119(4):467-73. doi: 10.1289/ehp.1002667.

27.

Evidence of dysregulation of dendritic cells in primary HIV infection.

Sabado RL, O'Brien M, Subedi A, Qin L, Hu N, Taylor E, Dibben O, Stacey A, Fellay J, Shianna KV, Siegal F, Shodell M, Shah K, Larsson M, Lifson J, Nadas A, Marmor M, Hutt R, Margolis D, Garmon D, Markowitz M, Valentine F, Borrow P, Bhardwaj N.

Blood. 2010 Nov 11;116(19):3839-52. doi: 10.1182/blood-2010-03-273763. Epub 2010 Aug 6.

28.

Genetic determinants of sensitivity to beryllium in mice.

Tarantino-Hutchison LM, Sorrentino C, Nadas A, Zhu Y, Rubin EM, Tinkle SS, Weston A, Gordon T.

J Immunotoxicol. 2009 Jun;6(2):130-5. doi: 10.1080/15476910902977399.

PMID:
19589099
29.

Worldwide distribution of HIV type 1 epitopes recognized by human anti-V3 monoclonal antibodies.

Cardozo T, Swetnam J, Pinter A, Krachmarov C, Nadas A, Almond D, Zolla-Pazner S.

AIDS Res Hum Retroviruses. 2009 Apr;25(4):441-50. doi: 10.1089/aid.2008.0188.

30.

Neutralization patterns and evolution of sequential HIV type 1 envelope sequences in HIV type 1 subtype B-infected drug-naive individuals.

Nyambi P, Burda S, Urbanski M, Heyndrickx L, Janssens W, Vanham G, Nadas A.

AIDS Res Hum Retroviruses. 2008 Dec;24(12):1507-19. doi: 10.1089/aid.2008.0154.

31.

Peptide-based antibody detection for tuberculosis diagnosis.

Shen G, Behera D, Bhalla M, Nadas A, Laal S.

Clin Vaccine Immunol. 2009 Jan;16(1):49-54. doi: 10.1128/CVI.00334-08. Epub 2008 Nov 12.

32.

Preferential use of the VH5-51 gene segment by the human immune response to code for antibodies against the V3 domain of HIV-1.

Gorny MK, Wang XH, Williams C, Volsky B, Revesz K, Witover B, Burda S, Urbanski M, Nyambi P, Krachmarov C, Pinter A, Zolla-Pazner S, Nadas A.

Mol Immunol. 2009 Feb;46(5):917-26. doi: 10.1016/j.molimm.2008.09.005. Epub 2008 Oct 25.

33.

Biomarkers for clinical and incipient tuberculosis: performance in a TB-endemic country.

Wanchu A, Dong Y, Sethi S, Myneedu VP, Nadas A, Liu Z, Belisle J, Laal S.

PLoS One. 2008 Apr 30;3(4):e2071. doi: 10.1371/journal.pone.0002071.

34.

Airport-related air pollution and noise.

Cohen BS, Bronzaft AL, Heikkinen M, Goodman J, Nádas A.

J Occup Environ Hyg. 2008 Feb;5(2):119-29. Erratum in: J Occup Environ Hyg. 2008 May;5(5):D61.

PMID:
18097935
35.
36.

Induction and prevention of carcinogenesis in rat skin exposed to space radiation.

Burns FJ, Tang MS, Frenkel K, Nádas A, Wu F, Uddin A, Zhang R.

Radiat Environ Biophys. 2007 Jun;46(2):195-9. Epub 2007 Mar 27.

PMID:
17387500
37.

CCR5 expression and duration of high risk sexual activity among HIV-seronegative men who have sex with men.

Thomas SM, Tse DB, Ketner DS, Rochford G, Meyer DA, Zade DD, Halkitis PN, Nádas A, Borkowsky W, Marmor M.

AIDS. 2006 Sep 11;20(14):1879-83.

38.

Distinct sequence patterns characterize the V3 region of HIV type 1 gp120 from subtypes A and C.

Felsövályi K, Nádas A, Zolla-Pazner S, Cardozo T.

AIDS Res Hum Retroviruses. 2006 Jul;22(7):703-8.

39.

Cross-clade neutralizing activity of human anti-V3 monoclonal antibodies derived from the cells of individuals infected with non-B clades of human immunodeficiency virus type 1.

Gorny MK, Williams C, Volsky B, Revesz K, Wang XH, Burda S, Kimura T, Konings FA, Nádas A, Anyangwe CA, Nyambi P, Krachmarov C, Pinter A, Zolla-Pazner S.

J Virol. 2006 Jul;80(14):6865-72.

40.
41.

The parity-related protection against breast cancer is compromised by cigarette smoke during rat pregnancy: observations on tumorigenesis and immunological defenses of the neonate.

Steinetz BG, Gordon T, Lasano S, Horton L, Ng SP, Zelikoff JT, Nadas A, Bosland MC.

Carcinogenesis. 2006 Jun;27(6):1146-52. Epub 2006 Feb 12.

PMID:
16474179
42.

Mapping and prediction of coal workers' pneumoconiosis with bioavailable iron content in the bituminous coals.

Huang X, Li W, Attfield MD, Nádas A, Frenkel K, Finkelman RB.

Environ Health Perspect. 2005 Aug;113(8):964-8.

43.

Effect of particulate and gaseous pollutants on spontaneous arrhythmias in aged rats.

Nadziejko C, Fang K, Narciso S, Zhong M, Su WC, Gordon T, Nádas A, Chen LC.

Inhal Toxicol. 2004 Jun;16(6-7):373-80.

PMID:
15204753
44.

Monitor-to-monitor temporal correlation of air pollution in the contiguous US.

Ito K, De Leon S, Thurston GD, Nádas A, Lippmann M.

J Expo Anal Environ Epidemiol. 2005 Mar;15(2):172-84.

PMID:
15199379
45.

The 'Fishing License' method for analysing the time course of effects in repeated measurements.

Nadziejko C, Chi Chen L, Nádas A, Hwang JS.

Stat Med. 2004 May 15;23(9):1399-411.

PMID:
15116349
46.

Exposure to chromium (VI) in the drinking water increases susceptibility to UV-induced skin tumors in hairless mice.

Davidson T, Kluz T, Burns F, Rossman T, Zhang Q, Uddin A, Nadas A, Costa M.

Toxicol Appl Pharmacol. 2004 May 1;196(3):431-7.

PMID:
15094314
47.

Arsenic-induced enhancement of ultraviolet radiation carcinogenesis in mouse skin: a dose-response study.

Burns FJ, Uddin AN, Wu F, Nádas A, Rossman TG.

Environ Health Perspect. 2004 Apr;112(5):599-603.

48.

Defining human immunodeficiency virus (HIV) type 1 immunotypes with six human monoclonal antibodies.

Nádas A, Zhong P, Burda S, Zekeng L, Urbanski M, Gorny MK, Zolla-Pazner S, Nyambi PN.

AIDS Res Hum Retroviruses. 2004 Jan;20(1):55-65.

PMID:
15000699
49.

The v3 loop is accessible on the surface of most human immunodeficiency virus type 1 primary isolates and serves as a neutralization epitope.

Gorny MK, Revesz K, Williams C, Volsky B, Louder MK, Anyangwe CA, Krachmarov C, Kayman SC, Pinter A, Nadas A, Nyambi PN, Mascola JR, Zolla-Pazner S.

J Virol. 2004 Mar;78(5):2394-404.

50.

Combined use of serum and urinary antibody for diagnosis of tuberculosis.

Singh KK, Dong Y, Hinds L, Keen MA, Belisle JT, Zolla-Pazner S, Achkar JM, Nadas AJ, Arora VK, Laal S.

J Infect Dis. 2003 Aug 1;188(3):371-7. Epub 2003 Jul 15.

PMID:
12870118

Supplemental Content

Support Center